CN104039341A - 用于治疗视网膜病症和疾病的anp(心钠素)、bnp(脑钠素)以及cnp(c型利钠肽)相关肽及其衍生物的方法和用途 - Google Patents

用于治疗视网膜病症和疾病的anp(心钠素)、bnp(脑钠素)以及cnp(c型利钠肽)相关肽及其衍生物的方法和用途 Download PDF

Info

Publication number
CN104039341A
CN104039341A CN201280062142.XA CN201280062142A CN104039341A CN 104039341 A CN104039341 A CN 104039341A CN 201280062142 A CN201280062142 A CN 201280062142A CN 104039341 A CN104039341 A CN 104039341A
Authority
CN
China
Prior art keywords
residue
compound
amino acid
disease
retinal disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280062142.XA
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·科兹洛夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KALOS THERAPEUTICS Inc
Original Assignee
KALOS THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KALOS THERAPEUTICS Inc filed Critical KALOS THERAPEUTICS Inc
Priority to CN201810139954.9A priority Critical patent/CN108653715A/zh
Publication of CN104039341A publication Critical patent/CN104039341A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280062142.XA 2011-12-16 2012-12-17 用于治疗视网膜病症和疾病的anp(心钠素)、bnp(脑钠素)以及cnp(c型利钠肽)相关肽及其衍生物的方法和用途 Pending CN104039341A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810139954.9A CN108653715A (zh) 2011-12-16 2012-12-17 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576720P 2011-12-16 2011-12-16
US61/576,720 2011-12-16
PCT/US2012/070190 WO2013090931A2 (en) 2011-12-16 2012-12-17 Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810139954.9A Division CN108653715A (zh) 2011-12-16 2012-12-17 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途

Publications (1)

Publication Number Publication Date
CN104039341A true CN104039341A (zh) 2014-09-10

Family

ID=48613379

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810139954.9A Pending CN108653715A (zh) 2011-12-16 2012-12-17 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途
CN201280062142.XA Pending CN104039341A (zh) 2011-12-16 2012-12-17 用于治疗视网膜病症和疾病的anp(心钠素)、bnp(脑钠素)以及cnp(c型利钠肽)相关肽及其衍生物的方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810139954.9A Pending CN108653715A (zh) 2011-12-16 2012-12-17 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途

Country Status (7)

Country Link
US (1) US20150045301A1 (enExample)
EP (1) EP2790714A4 (enExample)
JP (2) JP2015502368A (enExample)
CN (2) CN108653715A (enExample)
CA (1) CA2853204A1 (enExample)
HK (1) HK1202433A1 (enExample)
WO (1) WO2013090931A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419917B2 (en) 2020-04-07 2022-08-23 Drora Shevy Treatment for SARS-CoV-2 and other coronaviruses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238817A1 (en) * 2007-12-28 2009-09-24 Kalos Therapeutics Anti-cell proliferative compounds and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
JPH10273450A (ja) * 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
AU2005227870A1 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US20070049251A1 (en) 2005-08-31 2007-03-01 Mock Von A Method and system for wireless communication in emergency situations
EP2187928A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of anti-inflammatory peptide 1 as a therapeutic agent
RU2010114013A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение нейротрофического фактора для холинергических нейронов сетчатки (nfrcn) и хорионического гонадотропина бета (109-145) в качестве терапевтических средств
US20100204114A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a galanin peptide as a therapeutic agent
CA2699100A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
WO2011038066A2 (en) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
BR112012006579A2 (pt) * 2009-09-25 2016-11-22 Alcon Res Ltd agonistas de npr-b.
WO2011075471A2 (en) * 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238817A1 (en) * 2007-12-28 2009-09-24 Kalos Therapeutics Anti-cell proliferative compounds and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NURIA LARA-CASTILLO 等: "Atrial Natriuretic Peptide Reduces Vascular Leakage and Choroidal Neovascularization", 《THE AMERICAN JOURNAL OF PATHOLOGY》 *
XINYUAN ZHANG 等: "Apoptosis and Cell Proliferation in Proliferative Retinal Disorders: PCNA, Ki-67, Caspase-3, and PARP Expression", 《CURRENT EYE RESEARCH》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途

Also Published As

Publication number Publication date
EP2790714A2 (en) 2014-10-22
WO2013090931A2 (en) 2013-06-20
CA2853204A1 (en) 2013-06-20
EP2790714A4 (en) 2015-08-05
US20150045301A1 (en) 2015-02-12
WO2013090931A3 (en) 2013-10-31
CN108653715A (zh) 2018-10-16
JP2015502368A (ja) 2015-01-22
HK1202433A1 (en) 2015-10-02
JP2018024674A (ja) 2018-02-15

Similar Documents

Publication Publication Date Title
JP7693290B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
ES2748038T3 (es) Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
US10610568B2 (en) Compositions and methods of use for treating metabolic disorders
ES2828505T3 (es) Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
ES2815540T3 (es) Proteínas de fusión de FGF21 de acción prolongada y composición farmacéutica que comprende las mismas
EA010200B1 (ru) Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
CN102470156A (zh) 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途
US12048750B2 (en) Tissue-homing peptide conjugates and methods of use thereof
US12171834B2 (en) Compositions and methods for inhibiting the activity of LAR family phosphatases
BR112021008832A2 (pt) Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico
CN104039341A (zh) 用于治疗视网膜病症和疾病的anp(心钠素)、bnp(脑钠素)以及cnp(c型利钠肽)相关肽及其衍生物的方法和用途
Rehmani Developing an Oral-Insulin-Delivery System using GET-peptide-mediated transcytosis
HK40105119A (en) Compositions for treating neural injury by inhibiting the activity of lar family phosphatases
WO2014161095A1 (en) Crp40 fragments for the treatment of neurological disorders
WO2022029778A1 (en) Peptides for treating acute respiratory distress syndrome
HK40002768A (en) Compositions for treating neural injury by inhibiting the activity of lar family phosphatases
HK40002768B (en) Compositions for treating neural injury by inhibiting the activity of lar family phosphatases
HK1207303B (en) Compositions for use in treating neural injury by inhibiting the activity of lar family phosphatases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140910

RJ01 Rejection of invention patent application after publication